Literature DB >> 32405757

Attention-enhancing effects of propranolol and synergistic effects with nicotine.

Britta Hahn1, Cory K Olmstead2, Marie B Yuille2, Joshua J Chiappelli2, Ashleigh K Wells2.   

Abstract

Nicotine increases the output of every major neurotransmitter. In previous studies designed to identify the secondary neurotransmitter systems mediating nicotine's attention-enhancing effects in a rat model, the β-adrenoceptor antagonist propranolol blocked these effects. The present study was designed to test whether this mechanism held true in humans, thus guiding development of novel nicotinic agonists for cognitive enhancement. Twenty-six nonsmokers completed a nicotine (7 mg/24 h transdermally) x propranolol (40 mg p.o., body weight-adjusted) interaction study. Over four test days, each participant received double-placebo, nicotine only, propranolol only, and nicotine plus propranolol in randomized sequence before cognitive testing. No drug effects were seen in a visuospatial attention task. In the Rapid Visual Information Processing Task, performed in two 15-min blocks, neither drug alone significantly affected hit rate, but both drugs combined acted synergistically to alleviate its decrement over time in the first block and displayed additive beneficial effects in the second. In a change detection task, propranolol enhanced accuracy and reduced reaction time independent of nicotine presence. Propranolol also enhanced subjective self-reports of vigor. Overall, the findings were contrary to those hypothesized. Propranolol displayed beneficial effects on cognition, especially on sustaining performance over time. β-adrenoceptor activation by nicotine-induced noradrenaline release appeared to limit performance-enhancing effects of nicotine, because they were unmasked by β-adrenoceptor antagonism. The results suggest that cognitive effects of changes in β-adrenoceptor tone are context-dependent; contrary to rodent paradigms, human cognitive paradigms require no physical orienting in space but prolonged periods of remaining stationary while sustaining predictable processing demands.

Entities:  

Keywords:  Arousal; Nicotine; POMS; Propranolol; RVIP; SARAT; Sustained attention

Year:  2020        PMID: 32405757      PMCID: PMC7272290          DOI: 10.3758/s13415-020-00794-5

Source DB:  PubMed          Journal:  Cogn Affect Behav Neurosci        ISSN: 1530-7026            Impact factor:   3.282


  51 in total

1.  A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches.

Authors:  R V Fant; J E Henningfield; S Shiffman; K R Strahs; D P Reitberg
Journal:  Pharmacol Biochem Behav       Date:  2000-11       Impact factor: 3.533

Review 2.  Nicotinic acetylcholine receptors: from basic science to therapeutics.

Authors:  Raymond Hurst; Hans Rollema; Daniel Bertrand
Journal:  Pharmacol Ther       Date:  2012-08-25       Impact factor: 12.310

3.  Nicotinic receptors mediate the release of amino acid neurotransmitters in cultured cortical neurons.

Authors:  E López; C Arce; S Vicente; M J Oset-Gasque; M P González
Journal:  Cereb Cortex       Date:  2001-02       Impact factor: 5.357

4.  A CHRNA5 allele related to nicotine addiction and schizophrenia.

Authors:  L E Hong; X Yang; I Wonodi; C A Hodgkinson; D Goldman; O C Stine; E S Stein; G K Thaker
Journal:  Genes Brain Behav       Date:  2011-04-06       Impact factor: 3.449

5.  Meta-analysis of the acute effects of nicotine and smoking on human performance.

Authors:  Stephen J Heishman; Bethea A Kleykamp; Edward G Singleton
Journal:  Psychopharmacology (Berl)       Date:  2010-04-24       Impact factor: 4.530

6.  Effects of scopolamine and nicotine on human rapid information processing performance.

Authors:  K Wesnes; D M Warburton
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

7.  A test of the cognitive-enhancing potential of low-dose mecamylamine in healthy non-smokers.

Authors:  Marie B Yuille; Cory K Olmstead; Ashleigh K Wells; Britta Hahn
Journal:  Psychopharmacology (Berl)       Date:  2016-09-27       Impact factor: 4.530

8.  Nicotine enhances visuospatial attention by deactivating areas of the resting brain default network.

Authors:  Britta Hahn; Thomas J Ross; Yihong Yang; Insook Kim; Marilyn A Huestis; Elliot A Stein
Journal:  J Neurosci       Date:  2007-03-28       Impact factor: 6.167

Review 9.  Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists.

Authors:  Richard J Radek; Kathy L Kohlhaas; Lynne E Rueter; Eric G Mohler
Journal:  Curr Pharm Des       Date:  2010-01       Impact factor: 3.116

Review 10.  Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease.

Authors:  Simon N Haydar; John Dunlop
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

View more
  1 in total

1.  Nicotinic receptor modulation of the default mode network.

Authors:  Britta Hahn; Alexander N Harvey; Marta Concheiro-Guisan; Marilyn A Huestis; Thomas J Ross; Elliot A Stein
Journal:  Psychopharmacology (Berl)       Date:  2020-11-20       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.